This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BromSite

Sun Pharmaceutical Industries Ltd.

Drug Names(s): ISV-303, bromfenac 0.075% and DuraSite

Description: ISV-303 is a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. ISV-303 combines 0.075% of the non-steroidal anti-inflammatory (NSAID) bromfenac (Xibrom) with InSite Vision's DuraSite technology. InSite's DuraSite sustained delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. In preclinical studies, ISV-303 demonstrated a superior delivery and ocular distribution profile when compared to the commercially available bromfenac eye drop.

Deal Structure: InSite and Nicox
In February 2015, InSite announced that it has entered into a license agreement with Nicox for the development and commercialization of InSite's ophthalmic therapeutic products AzaSite (1% azithromycin), AzaSite Xtra (2% azithromycin) and BromSite (0.075% bromfenac). The agreement grants Nicox exclusive rights to commercialize all three products in Europe (including Eastern Europe), Middle East and Africa (EMEA). Under terms of the licensing agreement, InSite will receive an upfront payment of $3 million and potentially $13.75 million in milestone payments. Upon product launch, InSite will also receive tiered, mid-single digit to double-digit royalties.

QLT and InSite
In June 2015, QLT announced that it has signed a definitive agreement to acquire InSite Vision for $0.178 per share in an all-share transaction. Under the terms of the of the definitive agreement and plan of merger, at closing of the InSite Acquisition InSite Vision...See full deal structure in Biomedtracker

Partners: Nicox S.A.


BromSite News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug